Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gordon C Jayson

Showing results (91-100 of 126) with videos related to

Pageof 13
Sort By:
Lancet (London, England)|May 24, 2015
Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trialSean Kehoe, Jane Hook, Matthew Nankivell, et al.
Magnetic Resonance in Medicine|September 1, 2007
Organ-specific effects of oxygen and carbogen gas inhalation on tissue longitudinal relaxation timesJames P B O'Connor, Alan Jackson, Giovanni A Buonaccorsi, et al.
Magnetic Resonance in Medicine|December 20, 2008
Comparison of normal tissue R1 and R*2 modulation by oxygen and carbogenJames P B O'Connor, Josephine H Naish, Alan Jackson, et al.
Clinical Colorectal Cancer|December 13, 2025
Overall Survival for Bevacizumab Therapy in Metastatic Colorectal Cancer: An Updated Analysis of the TRAVASTIN StudyRosie Maye Solomon, Robert D Morgan, Laura Horsley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2014
Biomarkers and response to bevacizumab--responseFiona Collinson, Michelle Hutchinson, Rachel A Craven, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2013
Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selectionFiona Collinson, Michelle Hutchinson, Rachel A Craven, et al.
Cancer|June 3, 2019
High EMSY expression defines a BRCA-like subgroup of high-grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinumRobert L Hollis, Michael Churchman, Caroline O Michie, et al.
Journal of Medical Genetics|January 27, 2019
Prevalence of germline pathogenic <i>BRCA1/2</i> variants in sequential epithelial ovarian cancer casesRobert D Morgan, George J Burghel, Nicola Flaum, et al.
Cancers|February 11, 2023
Is Reflex Germline <i>BRCA1/2</i> Testing Necessary in Women Diagnosed with Non-Mucinous High-Grade Epithelial Ovarian Cancer Aged 80 Years or Older?Robert D Morgan, George J Burghel, Nicola Flaum, et al.
British Journal of Cancer|March 9, 2022
BRCA1/2 in non-mucinous epithelial ovarian cancer: tumour with or without germline testing?Robert D Morgan, George J Burghel, Nicola Flaum, et al.
Pageof 13

Showing results (91-100 of 126) with videos related to

Sort By:
Pageof 13
Lancet (London, England)|May 24, 2015
Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trialSean Kehoe, Jane Hook, Matthew Nankivell, et al.
Magnetic Resonance in Medicine|September 1, 2007
Organ-specific effects of oxygen and carbogen gas inhalation on tissue longitudinal relaxation timesJames P B O'Connor, Alan Jackson, Giovanni A Buonaccorsi, et al.
Magnetic Resonance in Medicine|December 20, 2008
Comparison of normal tissue R1 and R*2 modulation by oxygen and carbogenJames P B O'Connor, Josephine H Naish, Alan Jackson, et al.
Clinical Colorectal Cancer|December 13, 2025
Overall Survival for Bevacizumab Therapy in Metastatic Colorectal Cancer: An Updated Analysis of the TRAVASTIN StudyRosie Maye Solomon, Robert D Morgan, Laura Horsley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2014
Biomarkers and response to bevacizumab--responseFiona Collinson, Michelle Hutchinson, Rachel A Craven, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2013
Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selectionFiona Collinson, Michelle Hutchinson, Rachel A Craven, et al.
Cancer|June 3, 2019
High EMSY expression defines a BRCA-like subgroup of high-grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinumRobert L Hollis, Michael Churchman, Caroline O Michie, et al.
Journal of Medical Genetics|January 27, 2019
Prevalence of germline pathogenic <i>BRCA1/2</i> variants in sequential epithelial ovarian cancer casesRobert D Morgan, George J Burghel, Nicola Flaum, et al.
Cancers|February 11, 2023
Is Reflex Germline <i>BRCA1/2</i> Testing Necessary in Women Diagnosed with Non-Mucinous High-Grade Epithelial Ovarian Cancer Aged 80 Years or Older?Robert D Morgan, George J Burghel, Nicola Flaum, et al.
British Journal of Cancer|March 9, 2022
BRCA1/2 in non-mucinous epithelial ovarian cancer: tumour with or without germline testing?Robert D Morgan, George J Burghel, Nicola Flaum, et al.
Pageof 13